Skip to main content
Full access
Articles
Published Online: 10 September 2021

Association of ECT With Risks of All-Cause Mortality and Suicide in Older Medicare Patients

Abstract

Objective:

This observational study examined the effects of electroconvulsive therapy (ECT) on suicide and all-cause mortality risk in older psychiatric patients.

Methods:

Participants were Medicare-insured psychiatric inpatients age 65 or older. Patients receiving ECT were exact-matched to control subjects (in a 1:3 ratio) on age, gender, principal hospital diagnosis, past-year psychiatric hospitalizations, past-year suicide attempts, and Elixhauser comorbidity index. Cox proportional hazard models were risk-adjusted for race, year of hospitalization, rural-urban continuum code, year of index hospitalization, median income of zip code, and all matched covariates to estimate hazard ratios with 95% confidence intervals.

Results:

A total of 10,460 patients in the ECT group and 31,160 in the control group were included in the analyses (total N=41,620; 65.4% female; mean age, 74.7 years [SD=7.09]). Compared with the control group, patients receiving ECT had lower all-cause mortality for up to 1 year following hospital discharge (adjusted hazard ratio=0.61, 95% CI=0.56, 0.66). For death by suicide, 1-year survival analysis showed no group difference. A significant association was observed with suicide in the first months following ECT, but this pattern waned over time (1 month: hazard ratio=0.44, 95% CI=0.21, 0.91; 2 months: hazard ratio=0.52, 95% CI=0.29, 0.92; 3 months: hazard ratio=0.56, 95% CI=0.37, 0.92; 6 months: 0.87, 95% CI=0.59, 1.28; 12 months: 0.92, 95% CI=0.68, 1.25).

Conclusions:

In this observational study, ECT was associated with lower 1-year all-cause mortality and with short-lived protective effects on suicide risk. These findings support greater consideration of ECT for inpatients with mood disorders at short-term risk of suicide.

Formats available

You can view the full content in the following formats:

Supplementary Material

File (appi.ajp.2021.21040351.ds001.pdf)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1089 - 1097
PubMed: 34503341

History

Received: 8 April 2021
Revision received: 24 May 2021
Accepted: 12 July 2021
Published online: 10 September 2021
Published in print: December 2021

Keywords

  1. Depressive Disorders
  2. Major Depressive Disorder
  3. Electroconvulsive Therapy (ECT)
  4. Suicide and Self-Harm
  5. Bipolar and Related Disorders

Authors

Affiliations

Taeho Greg Rhee, Ph.D.
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington (Rhee); Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Rhee, Wilkinson); Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn. (Sint); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Olfson); Center for Pharmacoepidemiology and Treatment Science and Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, N.J. (Gerhard); Yale School of Public Health, Yale University, New Haven, Conn. (Busch); Interventional Psychiatry Service, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Wilkinson).
Kyaw Sint, Ph.D.
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington (Rhee); Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Rhee, Wilkinson); Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn. (Sint); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Olfson); Center for Pharmacoepidemiology and Treatment Science and Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, N.J. (Gerhard); Yale School of Public Health, Yale University, New Haven, Conn. (Busch); Interventional Psychiatry Service, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Wilkinson).
Mark Olfson, M.D., M.P.H.
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington (Rhee); Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Rhee, Wilkinson); Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn. (Sint); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Olfson); Center for Pharmacoepidemiology and Treatment Science and Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, N.J. (Gerhard); Yale School of Public Health, Yale University, New Haven, Conn. (Busch); Interventional Psychiatry Service, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Wilkinson).
Tobias Gerhard, Ph.D.
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington (Rhee); Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Rhee, Wilkinson); Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn. (Sint); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Olfson); Center for Pharmacoepidemiology and Treatment Science and Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, N.J. (Gerhard); Yale School of Public Health, Yale University, New Haven, Conn. (Busch); Interventional Psychiatry Service, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Wilkinson).
Susan H. Busch, Ph.D.
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington (Rhee); Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Rhee, Wilkinson); Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn. (Sint); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Olfson); Center for Pharmacoepidemiology and Treatment Science and Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, N.J. (Gerhard); Yale School of Public Health, Yale University, New Haven, Conn. (Busch); Interventional Psychiatry Service, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Wilkinson).
Samuel T. Wilkinson, M.D. [email protected]
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington (Rhee); Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Rhee, Wilkinson); Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn. (Sint); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Olfson); Center for Pharmacoepidemiology and Treatment Science and Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, N.J. (Gerhard); Yale School of Public Health, Yale University, New Haven, Conn. (Busch); Interventional Psychiatry Service, Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (Wilkinson).

Notes

Send correspondence to Dr. Wilkinson ([email protected]).

Competing Interests

Dr. Gerhard has received personal fees from Bristol-Myers Squibb, Eli Lilly, Eisai, and Intra-Cellular Therapies. Dr. Wilkinson has received contract funding from Janssen, Oui Therapeutics, and Sage Therapeutics for the conduct of clinical trials administered through Yale University, and he has received consulting fees from Biohaven Pharmaceuticals, Janssen, Oui Therapeutics, and Sage Therapeutics. The other authors report no financial relationships with commercial interests.

Funding Information

Supported by NIMH grant R21MH117438 and by a young investigator grant (to Dr. Wilkinson) from the American Foundation for Suicide Prevention. Dr. Wilkinson also acknowledges support from the Agency for Healthcare Research and Quality (K12HS023000).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share